Comparable incidence and severity of cytomegalovirus infections following T cell-depleted allogeneic stem cell transplantation preceded by reduced intensity or myeloablative conditioning

Bone Marrow Transplantation

Volumn 40, Issue 2, 2007, Pages 137-143

  Kalpoe, J S ^a   van der Heiden, P L J ^a   Vaessen, N ^a   Claas, E C J ^a   Barge, R M ^a   Kroes, A C M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; GANCICLOVIR; METHYLPREDNISOLONE; PREDNISONE; THYMOCYTE ANTIBODY; VALGANCICLOVIR; VIRUS DNA;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DONOR LYMPHOCYTE INFUSION; DRUG DOSE REGIMEN; DRUG SAFETY; FEMALE; HUMAN; INCIDENCE; INFECTION RISK; LYMPHOCYTE DEPLETION; MALE; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SURVIVAL RATE; SURVIVAL TIME; VIRUS LOAD; VIRUS REACTIVATION; WHOLE BODY RADIATION;

ADULT; AGED; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC NEOPLASMS; HUMANS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; RECURRENCE; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 34447277110     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705701     Document Type: Article

References (25)

1. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
2. Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O'Brien S et al. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824.
3. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
4. Barge RM, Osanto S, Marijt WA, Starrenburg CW, Fibbe WE, Nortier JW et al. Minimal GVHD following in-vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors. Exp Hematol 2003; 31: 865-872.
5. Junghanss C, Marr KA. Infectious risks and outcomes after stem cell transplantation: Are nonmyeloablative transplants changing the picture? Curr Opin Infect Dis 2002; 15: 347-353.
6. Ljungman P, Reusser P, de la CR, Einsele H, Engelhard D, Ribaud P et al. Management of CMV infections: Recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant 2004; 33: 1075-1081.
7. Ljungman P. Beta-herpesvirus challenges in the transplant recipient. J Infect Dis 2002; 186: S99-S109.
8. Crampacker CS. Ganciclovir. N Engl J Med 1996; 335: 721-729.
9. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355 2032-2036.
10. Schafer P, Tenschert W, Cremaschi L, Schroter M, Zollner B, Laufs R. Area under the viraemia curve versus absolute viral load: Utility for predicting symptomatic cytomegalovirus infections in kidney transplant patients. J Med Virol 2001; 65: 85-89.
11. Barge RM, Brouwer RE, Beersma MF, Starrenburg CW, Zwinderman AH, Hale G et al. Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation: Effect of stem cell source on short- and long-term outcome. Bone Marrow Transplant 2001; 27 1053-1058.
12. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
13. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of Seattle patients. Am J Med 20; 69 204-217.
14. Kalpoe JS, Kroes AC, de Jong MD, Schinkel J, de Brouwer CS, Beersma MF et al. Validation of clinical application of cytomegalovirus plasma DNA load measurement and definition of treatment criteria by analysis of correlation to antigen detection. J Clin Microbiol 2004; 42: 1498-1504.
15. Journot V, Chene G, Joly P, Saves M, Jacqmin-Gadda H, Molina JM et al. Viral load as a primary outcome in human immunodeficiency virus trials: A review of statistical analysis methods. Control Clin Trials 2001; 22: 639-658.
16. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-620.
17. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
18. Mackinnon S, Thomson K, Morris E, Kottaridis PD, Peggs KS. Reduced intensity transplantation: Where are we now? Hematol J 2004; 5 S34-S38.
19. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003; 9: 543-558.
20. Junghanss C, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002; 99: 1978-1985.
21. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: Potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99: 4357-4363.
22. Nachbaur D, Larcher C, Kircher B, Eibl G, Nussbaumer W, Gunsilius E et al. Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation. Ann Hematol 2003; 82: 621-627.
23. Schetelig J, Oswald O, Steuer N, Radonic A, Thulke S, Held TK et al. Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia. Bone Marrow Transplant 2003; 32: 695-701.
24. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004; 103: 2003-2008.
25. Ljungman P, Perez-Bercoff L, Jonsson J, Avetisyan G, Sparrelid E, Aschan J et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006; 91: 78-83.